| Year |
Citation |
Score |
| 2020 |
Cooper JT, Lloyd A, Sanchez JJG, Sörstadius E, Briggs A, McFarlane P. Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. Health and Quality of Life Outcomes. 18: 310. PMID 32957990 DOI: 10.1186/S12955-020-01559-X |
0.317 |
|
| 2020 |
Dakin HA, Leal J, Briggs A, Clarke P, Holman RR, Gray A. Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X20916442. PMID 32431211 DOI: 10.1177/0272989X20916442 |
0.329 |
|
| 2019 |
Tremblay G, Westley T, Forsythe A, Pelletier C, Briggs A. A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis. Journal of Comparative Effectiveness Research. 8: 1265-1298. PMID 31774340 DOI: 10.2217/Cer-2019-0064 |
0.313 |
|
| 2019 |
Alam MF, Briggs A. Artificial neural network metamodel for sensitivity analysis in a total hip replacement health economic model. Expert Review of Pharmacoeconomics & Outcomes Research. PMID 31491359 DOI: 10.1080/14737167.2019.1665512 |
0.306 |
|
| 2019 |
Dick K, Briggs A, Ohsfeldt R, Sydendal Grand T, Buchs S. A quality of life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. Journal of Medical Economics. 1. PMID 31352853 DOI: 10.1080/13696998.2019.1649268 |
0.318 |
|
| 2019 |
Paly VF, Naya I, Gunsoy NB, Driessen MT, Risebrough N, Briggs A, Ismaila AS. Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. International Journal of Chronic Obstructive Pulmonary Disease. 14: 939-951. PMID 31190781 DOI: 10.2147/Copd.S188898 |
0.381 |
|
| 2019 |
Xin Y, Davies A, McCombie L, Briggs A, Messow CM, Grieve E, Leslie WS, Taylor R, Lean MEJ. Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight-Plus weight management programme within a primary care randomized controlled trial. Diabetic Medicine : a Journal of the British Diabetic Association. PMID 31026353 DOI: 10.1111/Dme.13981 |
0.325 |
|
| 2019 |
Thompson CW, Oliveira EMSd, Tilley S, Elizalde A, Botha W, Briggs A, Cummins S, Leyland A, Roe J, Aspinall P, Brookfield K, Mitchell R. Health impacts of environmental and social interventions designed to increase deprived communities’ access to urban woodlands: a mixed-methods study Public Health Research. 7: 1-172. PMID 30620516 DOI: 10.3310/Phr07020 |
0.302 |
|
| 2019 |
Fasching PA, Huang M, Cortés J, Zhao J, O’Shaughnessy J, Hu P, Haiderali A, Karantza V, Aktan G, Briggs A, Ramsey S, Qi CZ, Xie J, Gu C, Qian K, et al. Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz240.067 |
0.303 |
|
| 2018 |
Xin Y, Davies A, McCombie L, Briggs A, Messow CM, Grieve E, Leslie WS, Taylor R, Lean MEJ. Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. The Lancet. Diabetes & Endocrinology. PMID 30581081 DOI: 10.1016/S2213-8587(18)30346-2 |
0.327 |
|
| 2018 |
Driessen M, Shah D, Risebrough N, Baker T, Naya I, Briggs A, Ismaila AS. Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. Respiratory Medicine. 145: 130-137. PMID 30509701 DOI: 10.1016/J.Rmed.2018.10.024 |
0.316 |
|
| 2018 |
Hatswell AJ, Bullement A, Briggs A, Paulden M, Stevenson MD. Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. Pharmacoeconomics. PMID 30051268 DOI: 10.1007/S40273-018-0697-3 |
0.311 |
|
| 2018 |
Ford TJ, Corcoran D, Oldroyd KG, McEntegart M, Rocchiccioli P, Watkins S, Brooksbank K, Padmanabhan S, Sattar N, Briggs A, McConnachie A, Touyz R, Berry C. Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. American Heart Journal. 201: 86-94. PMID 29803987 DOI: 10.1016/J.Ahj.2018.03.010 |
0.323 |
|
| 2018 |
Shah D, Driessen M, Risebrough N, Baker T, Naya I, Briggs A, Ismaila AS. Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation : C/E. 16: 17. PMID 29773969 DOI: 10.1186/S12962-018-0101-3 |
0.317 |
|
| 2018 |
Stollenwerk B, Iannazzo S, Akehurst R, Adena M, Briggs A, Dehmel B, Parfrey P, Belozeroff V. A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. Pharmacoeconomics. PMID 29392552 DOI: 10.1007/S40273-017-0605-2 |
0.313 |
|
| 2018 |
Ismaila A, Driessen M, Briggs A, Risebrough N, Naya I, Gunsoy N, Paly V. Economic and quality of life consequences of clinically important deterioration in patients with COPD: results from the TORCH study European Respiratory Journal. 52. DOI: 10.1183/13993003.Congress-2018.Oa1660 |
0.379 |
|
| 2017 |
McMurray JJV, Trueman D, Hancock E, Cowie MR, Briggs A, Taylor M, Mumby-Croft J, Woodcock F, Lacey M, Haroun R, Deschaseaux C. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart (British Cardiac Society). PMID 29269379 DOI: 10.1136/Heartjnl-2016-310661 |
0.308 |
|
| 2017 |
Grieve E, Hesselgreaves H, Wu O, Chalkidou K, Ruiz F, Smith P, Li R, Morris L, Briggs A. The Value of Health Technology Assessment: a mixed methods framework F1000research. 6. DOI: 10.7490/F1000Research.1115169.1 |
0.32 |
|
| 2017 |
Grieve E, Briggs A. A Methodological Approach for Measuring the Impact of HTA F1000research. 6. DOI: 10.7490/F1000Research.1113738.1 |
0.306 |
|
| 2017 |
Driessen M, Risebrough N, Briggs A, Ismaila A, Shah D, Naya I, Baker TM. Cost effectiveness of umeclidinium bromide 62.5μg plus ICS/LABA versus ICS/LABA in COPD European Respiratory Journal. 50. DOI: 10.1183/1393003.Congress-2017.Pa2790 |
0.362 |
|
| 2017 |
Driessen M, Risebrough N, Briggs A, Ismaila A, Shah D, Naya I, Baker TM. Cost-effectiveness of umeclidinium bromide 62.5µg or alternative LAMA plus ICS/LABA in COPD European Respiratory Journal. 50. DOI: 10.1183/1393003.Congress-2017.Pa2789 |
0.358 |
|
| 2017 |
Tremblay G, Bhor M, Roy A, Elliott B, Dolph M, Forsythe A, Briggs A. Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia Blood. 130: 2146-2146. DOI: 10.1182/Blood.V130.Suppl_1.2146.2146 |
0.382 |
|
| 2017 |
Baker T, Paly V, Sabater J, Gupte-Singh K, Beyhaghi H, Kotapati S, Rao S, Briggs A. Cost-Effectiveness of Nivolumab (NIVO) Combined with Ipilimumab (IPI) Compared with Nivo and Ipi Monotherapies in The First-Line Treatment of Advanced Melanoma in The United States: Analysis Using 28-Month Overall Survival (OS) Data from Checkmate 067 Value in Health. 20. DOI: 10.1016/J.Jval.2017.08.218 |
0.312 |
|
| 2017 |
Bouttell J, Hawkins N, Briggs A. Identifying Cost Effective Methods of Health Technology Assessment for Developers – The Need for Fast and Frugal Evaluation Value in Health. 20. DOI: 10.1016/J.Jval.2017.08.2031 |
0.333 |
|
| 2017 |
Kohli-Lynch C, Boyd K, Briggs A, Delles C. A Framework for the Cost-Effectiveness Analysis of Novel Biomarker Testing in Cardiovascular Disease Value in Health. 20. DOI: 10.1016/J.Jval.2017.08.040 |
0.347 |
|
| 2016 |
Kay G, Ma E, Woods B, Eaton J, Sajosi P, Engstrom A, Selby R, Benson E, Teasell J, Richhariya A, Briggs A, Bonthapally V. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 19. PMID 28152950 DOI: 10.1200/Jco.2016.34.7_Suppl.19 |
0.322 |
|
| 2016 |
Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, Teerawattananon Y, Asfaw E, Lopert R, Culyer AJ, Walker DG. The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 19: 921-928. PMID 27987641 DOI: 10.1016/J.Jval.2016.04.015 |
0.324 |
|
| 2016 |
Bouttell J, Lewsey J, Geue C, Antony G, Briggs A, McCartney G, Hutchinson S, Graham L, Heydtmann M. The SCottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. Plos One. 11: e0162980. PMID 27783619 DOI: 10.1371/Journal.Pone.0162980 |
0.32 |
|
| 2016 |
Wildman J, McMeekin P, Grieve E, Briggs A. Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. Social Science & Medicine (1982). 169: 141-148. PMID 27721138 DOI: 10.1016/J.Socscimed.2016.09.033 |
0.32 |
|
| 2016 |
Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, Lloyd A, Norman R. Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 19: 704-719. PMID 27712695 DOI: 10.1016/J.Jval.2016.06.001 |
0.358 |
|
| 2016 |
Tremblay G, Livings C, Crowe L, Kapetanakis V, Briggs A. Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. Clinicoeconomics and Outcomes Research : Ceor. 8: 323-33. PMID 27418847 DOI: 10.2147/Ceor.S107498 |
0.325 |
|
| 2016 |
Morton A, Adler AI, Bell D, Briggs A, Brouwer W, Claxton K, Craig N, Fischer A, McGregor P, van Baal P. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. Health Economics. 25: 933-8. PMID 27374115 DOI: 10.1002/Hec.3366 |
0.336 |
|
| 2016 |
Lee D, Porter J, Hertel N, Hatswell AJ, Briggs A. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. PMID 27177756 DOI: 10.1007/S40259-016-0178-1 |
0.339 |
|
| 2016 |
Hoogendoorn M, Feenstra T, Asukai Y, Briggs A, Hansen R, Leidl R, Risebrough N, Samyshkin Y, Wacker M, Mölken MR. External validation of exacerbation and mortality outcomes of health economic decision models for COPD European Respiratory Journal. 48. DOI: 10.1183/13993003.Congress-2016.Pa3120 |
0.374 |
|
| 2016 |
Tremblay G, Forsythe A, Bal V, Santra S, Briggs A. Cost-Effectiveness Analysis of Ofatumumab As a Treatment for Relapsed Chronic Lymphocytic Leukemia in the United States Blood. 128: 2366-2366. DOI: 10.1182/Blood.V128.22.2366.2366 |
0.399 |
|
| 2016 |
Leyland A, Ouédraogo S, Gray R, Bond L, Briggs A, Nam J, Wood R, Dundas R. OP86 Evaluating Health in Pregnancy grants in Scotland: a natural experiment Journal of Epidemiology and Community Health. 70. DOI: 10.1136/Jech-2016-208064.86 |
0.315 |
|
| 2016 |
Lewsey J, Blutell J, Geue C, Antony G, Briggs A, McCartney G, Hutchinson S, Graham L, Heydtmann M. PTH-104 Hospital Admissions and Associated Costs of Alcoholic Liver Disease in Scotland Between 1991 and 2011 Gut. 65. DOI: 10.1136/Gutjnl-2016-312388.508 |
0.313 |
|
| 2016 |
Baker T, Paly V, Sabater J, Okoro T, Kotapati S, Briggs A. Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced Melanoma Value in Health. 19. DOI: 10.1016/J.Jval.2016.09.2198 |
0.308 |
|
| 2016 |
Moore P, Briggs A, Davies A, Sculpher M, Kun K, Magnuson E, Cohen D, Mellstrom C. Ticagrelor Treatment for Prevention of Cardiovascular Events in High Risk Post Myocardial Infarction Patients: Cost-Effectiveness Analysis Using Evidence From The Pegasus-Timi 54 Trial Value in Health. 19. DOI: 10.1016/J.Jval.2016.09.1775 |
0.317 |
|
| 2016 |
Moore P, Briggs A, Davies A, Sculpher M, Williams J, Fenwick E, Wetering Gvd, Magnuson E, Cohen D, Haalen Hv, Mellstrom C. Cost-Effectiveness of Ticagrelor 60 Mg in High-Risk Post-Mi Patients From A Dutch Societal Perspective Value in Health. 19. DOI: 10.1016/J.Jval.2016.09.1771 |
0.306 |
|
| 2016 |
Stollenwerk B, Iannazzo S, Akehurst R, Adena M, Briggs A, Dehmel B, Parfrey P, Belozeroff V. Assessing The Cost-Utility of Etelcalcetide: A Markov Model Value in Health. 19: A519. DOI: 10.1016/J.Jval.2016.09.1003 |
0.323 |
|
| 2015 |
Li HK, Scarborough M, Zambellas R, Cooper C, Rombach I, Walker AS, Lipsky BA, Briggs A, Seaton A, Atkins B, Woodhouse A, Berendt A, Byren I, Angus B, Pandit H, et al. Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. Trials. 16: 583. PMID 26690812 DOI: 10.1186/S13063-015-1098-Y |
0.303 |
|
| 2015 |
Nam J, Briggs A, Layland J, Oldroyd KG, Curzen N, Sood A, Balachandran K, Das R, Junejo S, Eteiba H, Petrie MC, Lindsay M, Watkins S, Corbett S, O'Rourke B, et al. Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation : C/E. 13: 19. PMID 26578850 DOI: 10.1186/S12962-015-0045-9 |
0.373 |
|
| 2015 |
Hoogendoorn M, Feenstra T, Asukai Y, Briggs A, Borg S, Dal Negro R, Hansen RN, Jansson S, Wacker M, Risebrough N, Samyshkin Y, Leidl R, Rutten van-Mölken M. Patient Heterogeneity In Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (Copd): are Current Models Suitable to Evaluate Personalized Medicine. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A694. PMID 26533890 DOI: 10.1016/J.Jval.2015.09.2586 |
0.308 |
|
| 2015 |
McMurray JJ, Cowie MR, Cohen AA, Briggs A, de Pouvourville G, Taylor M, Hancock E, Trueman D, Mumby-Croft J, Haroun R, Deschaseaux C. A New Cost-Effectiveness Modelling Approach In Chronic Heart Failure With Reduced Ejection Fraction. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A394. PMID 26532224 DOI: 10.1016/J.Jval.2015.09.887 |
0.353 |
|
| 2015 |
Devereux G, Cotton S, Barnes P, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Fielding S, Gompertz S, Haughney J, Lee AJ, McCormack K, McPherson G, et al. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials. 16: 267. PMID 26058585 DOI: 10.1186/S13063-015-0782-2 |
0.31 |
|
| 2015 |
Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, Briggs A, Sullivan SD. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: 161-72. PMID 25773551 DOI: 10.1016/J.Jval.2015.02.001 |
0.364 |
|
| 2015 |
Old O, Moayyedi P, Love S, Roberts C, Hapeshi J, Foy C, Stokes C, Briggs A, Jankowski J, Barr H. Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. Journal of Medical Screening. PMID 25767103 DOI: 10.1177/0969141315575052 |
0.308 |
|
| 2015 |
Wolowacz S, Pearson I, Shannon P, Chubb B, Gundgaard J, Davies M, Briggs A. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabetic Medicine : a Journal of the British Diabetic Association. 32: 1023-35. PMID 25484028 DOI: 10.1111/Dme.12663 |
0.324 |
|
| 2015 |
Campbell JD, McQueen RB, Libby AM, Spackman DE, Carlson JJ, Briggs A. Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 35: 596-607. PMID 25349188 DOI: 10.1177/0272989X14556510 |
0.301 |
|
| 2015 |
Stollenwerk B, Lhachimi SK, Briggs A, Fenwick E, Caro JJ, Siebert U, Danner M, Gerber-Grote A. Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. Health Economics. 24: 481-90. PMID 24590819 DOI: 10.1002/Hec.3041 |
0.322 |
|
| 2015 |
Nam J, Briggs A, Layland J, Oldroyd K, Curzen N, Sood A, Balachandran K, Das R, Junejo S, Eteiba H, Petrie M, Watkins S, Corbett S, O’Rourke B, O’Donnell A, et al. Fractional Flow Reserve (Ffr) Versus Angiography In Guiding Management To Optimize Outcomes In Non-St Elevation Myocardial Infarction (Famous - Nstemi) Health Economic Analysis Journal of the American College of Cardiology. 65. DOI: 10.1016/S0735-1097(15)60233-9 |
0.307 |
|
| 2015 |
Nam J, Berry C, Henderson R, Briggs A. Economic Modelling In Randomized Controlled Trial (Rct)-Based Economic Evaluations: Empirical Examples Of Its Effect On The Precision Of Economic And Decision Outcomes Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.048 |
0.316 |
|
| 2014 |
Hudgens S, Briggs A, Velikova G, Forsythe A, McCutcheon S, Kind P. 1046PIMPACT OF TREATMENT WITH ERIBULIN (ERI) OR CAPECITABINE (CAP) FOR METASTATIC BREAST CANCER (MBC) ON EQ-5D UTILITY DERIVED FROM EORTC QLQ-C30. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv360. PMID 28171259 DOI: 10.1093/Annonc/Mdu341.10 |
0.345 |
|
| 2014 |
Xenakis A, Beckerman R, Chhatwal J, Gregory SA, Briggs A. A decision-analytic model of idelalisib in relapsed or refractory patients with follicular lymphoma in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 30. PMID 28141450 DOI: 10.1200/Jco.2014.32.30_Suppl.30 |
0.311 |
|
| 2014 |
Briggs A. Rational allocation of resources available for healthcare: understanding cost effectiveness analyst. Journal of the International Aids Society. 17: 19492. PMID 25394001 DOI: 10.7448/Ias.17.4.19492 |
0.373 |
|
| 2014 |
Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, Annesi-Maesano I, Anto JM, Bachert C, Baena-Cagnani CE, Bai C, Baigenzhin A, ... ... Briggs A, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). The European Respiratory Journal. 44: 304-23. PMID 24925919 DOI: 10.1183/09031936.00014614 |
0.331 |
|
| 2014 |
Campbell JD, McQueen RB, Briggs A. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Annals of the American Thoracic Society. 11: S105-11. PMID 24559022 DOI: 10.1513/Annalsats.201309-295Rm |
0.369 |
|
| 2014 |
Smith N, Xenakis A, Beckerman R, Chhatwal J, Gregory SA, Briggs A. A decision-analytic model of idelalisib in relapsed or refractory patients with indolent non-Hodgkin lymphoma. Journal of Clinical Oncology. 32: e17655-e17655. DOI: 10.1200/Jco.2014.32.15_Suppl.E17655 |
0.316 |
|
| 2013 |
Kent S, Briggs A, Eckermann S, Berry C. Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients. International Journal of Technology Assessment in Health Care. 29: 435-42. PMID 24290337 DOI: 10.1017/S0266462313000433 |
0.332 |
|
| 2013 |
Garrison LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 16: 703-19. PMID 23947963 DOI: 10.1016/J.Jval.2013.04.011 |
0.361 |
|
| 2013 |
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Bjog : An International Journal of Obstetrics and Gynaecology. 120: 765-70. PMID 23565948 DOI: 10.1111/1471-0528.12241 |
0.313 |
|
| 2012 |
Tappin DM, Bauld L, Tannahill C, de Caestecker L, Radley A, McConnachie A, Boyd K, Briggs A, Grant L, Cameron A, Macaskill S, Sinclair L, Friel B, Coleman T. The cessation in pregnancy incentives trial (CPIT): study protocol for a randomized controlled trial. Trials. 13: 113. PMID 22818493 DOI: 10.1186/1745-6215-13-113 |
0.303 |
|
| 2012 |
Pearson I, Wolowacz S, Irving A, Brockbank J, Chubb B, Gundgaard J, Briggs A, Davies MJ. PDB19 A Systematic Review of Recent Data Describing the Risk of Complications in Type 1 Diabetes Mellitus Patients Value in Health. 15. DOI: 10.1016/J.Jval.2012.08.1662 |
0.307 |
|
| 2012 |
Chollet M, Briggs A, Brin S, Dain MP, Meneghini L, Bergenstal R. PDB43 The Cost of Hypoglycemia in Diabetes: Defining the Severity of the Hypoglycemic Event is Key to Understanding the Economic Burden Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.964 |
0.3 |
|
| 2011 |
Barton P, Andronis L, Briggs A, McPherson K, Capewell S. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. Bmj (Clinical Research Ed.). 343: d4044. PMID 21798967 DOI: 10.1136/Bmj.D4044 |
0.338 |
|
| 2011 |
Bousquet J, Schünemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, Demoly P, Durham S, Carlsen KH, Malling HJ, Passalacqua G, Simons FE, Anto J, Baena-Cagnani CE, Bergmann KC, ... ... Briggs AH, et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy. 66: 765-74. PMID 21496059 DOI: 10.1111/J.1398-9995.2011.02590.X |
0.303 |
|
| 2011 |
Cummins E, Asseburg C, Punekar YS, Shore E, Morris J, Briggs A, Fenwick E. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value in Health. 14: 15-23. PMID 21211482 DOI: 10.1016/J.Jval.2010.10.016 |
0.381 |
|
| 2011 |
Murphy A, Fenwick E, Briggs A, Neilson M. How best to handle the evidence in a cost-effectiveness analysis of TAVI in the UK Trials. 12: 1-1. DOI: 10.1186/1745-6215-12-S1-A46 |
0.351 |
|
| 2010 |
Kuntz KM, Fenwick E, Briggs A. Appropriate cohorts for cost-effectiveness analysis: to mix or not to mix? Medical Decision Making : An International Journal of the Society For Medical Decision Making. 30: 424-5. PMID 20634547 DOI: 10.1177/0272989X10375038 |
0.327 |
|
| 2010 |
Briggs A. Transportability of Comparative Effectiveness and Cost-Effectiveness between Countries Value in Health. 13. PMID 20618791 DOI: 10.1111/J.1524-4733.2010.00751.X |
0.37 |
|
| 2010 |
Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Gustafson P, Briggs A, Montaner JS. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. Aids (London, England). 24: 1929-35. PMID 20588171 DOI: 10.1097/Qad.0B013E32833Af85D |
0.351 |
|
| 2010 |
Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Calverley PMA, Jones PW, Vestbo J. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study European Respiratory Journal. 35: 532-539. PMID 19717476 DOI: 10.1183/09031936.00153108 |
0.367 |
|
| 2010 |
Roberts NJ, Boyd K, Briggs A, Caress AL, Partridge MR. S10 Is it cost-effective to replace nurses with lay asthma educators in primary care? Thorax. 65. DOI: 10.1136/Thx.2010.150912.10 |
0.34 |
|
| 2010 |
Geue C, Lorgelly P, Lewsey J, Briggs A, Hart C. 063 Population ageing in Scotland: an analysis of the implications for healthcare expenditure using the Renfrew/Paisley study Journal of Epidemiology and Community Health. 64. DOI: 10.1136/Jech.2010.120956.63 |
0.347 |
|
| 2009 |
Levy AR, Szabo S, Briggs A, Pleil A, Davie A, Zlateva G, Javitt J. Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. Journal of Ophthalmology. 2009: 540431. PMID 20339464 DOI: 10.1155/2009/540431 |
0.317 |
|
| 2009 |
Levy A, Harrigan B, Johnston K, Briggs A. Comparative effectiveness research through the looking glass. Medical Decision Making. 29. PMID 19959806 DOI: 10.1177/0272989X09351590 |
0.305 |
|
| 2008 |
Eckermann S, Briggs A, Willan AR. Health technology assessment in the cost-disutility plane. Medical Decision Making. 28: 172-181. PMID 18356312 DOI: 10.1177/0272989X07312474 |
0.358 |
|
| 2008 |
Hirst A, Dutton S, Wu O, Briggs A, Edwards C, Waldenmaier L, Maresh M, Nicholson A, McPherson K. A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study. Health Technology Assessment (Winchester, England). 12: 1-248, iii. PMID 18331704 DOI: 10.3310/Hta12050 |
0.326 |
|
| 2007 |
Fenwick E, Briggs A. Cost-Effectiveness Acceptability Curves in the Dock: Case Not Proven? Medical Decision Making. 27: 93-95. PMID 17409358 DOI: 10.1177/0272989X07300071 |
0.327 |
|
| 2007 |
Ossa DF, Briggs A, McIntosh E, Cowell W, Littlewood T, Sculpher M. Recombinant erythropoietin for chemotherapy-related anaemia : Economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods Pharmacoeconomics. 25: 223-237. PMID 17335308 DOI: 10.2165/00019053-200725030-00005 |
0.306 |
|
| 2007 |
Lu G, Ades AE, Sutton AJ, Cooper NJ, Briggs AH, Caldwell DM. Meta-analysis of mixed treatment comparisons at multiple follow-up times. Statistics in Medicine. 26: 3681-99. PMID 17285571 DOI: 10.1002/Sim.2831 |
0.325 |
|
| 2007 |
Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research & Policy. 12: 56-58. PMID 17244400 DOI: 10.1258/135581907779497567 |
0.309 |
|
| 2007 |
Campbell H, Briggs A, Buxton M, Kim L, Thompson S. The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. Journal of Health Services Research & Policy. 12: 11-17. PMID 17244392 DOI: 10.1258/135581907779497594 |
0.312 |
|
| 2006 |
Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. Bmj. 333: 1145-1145. PMID 17098764 DOI: 10.1136/Bmj.38993.731725.Be |
0.341 |
|
| 2006 |
Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment. 10: 1-222. PMID 16959170 DOI: 10.3310/Hta10340 |
0.373 |
|
| 2006 |
Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Health Economics. 15: 1-4. PMID 16365910 DOI: 10.1002/Hec.1081 |
0.358 |
|
| 2005 |
Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S. Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report Value in Health. 8: 521-533. PMID 16176491 DOI: 10.1111/J.1524-4733.2005.00045.X |
0.36 |
|
| 2005 |
O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, Willan A. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics. 23: 529-36. PMID 15960550 DOI: 10.2165/00019053-200523060-00001 |
0.359 |
|
| 2005 |
Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. The Lancet. 365: 1779-1785. PMID 15910950 DOI: 10.1016/S0140-6736(05)63014-0 |
0.347 |
|
| 2005 |
Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value in Health. 8: 1-2. PMID 15841888 DOI: 10.1111/J.1524-4733.2005.08101.X |
0.371 |
|
| 2004 |
Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. Health Economics. 13: 405-15. PMID 15127421 DOI: 10.1002/Hec.903 |
0.357 |
|
| 2003 |
Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine. 20: 442-450. PMID 12786677 DOI: 10.1046/J.1464-5491.2003.00972.X |
0.342 |
|
| 2002 |
Goeree R, O'Brien BJ, Blackhouse G, Marshall J, Briggs A, Lad R. Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 5: 312-28. PMID 12102694 DOI: 10.1046/J.1524-4733.2002.54145.X |
0.33 |
|
| 2001 |
Briggs A, Tambour M. The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions Drug Information Journal. 35: 1455-1468. DOI: 10.1177/009286150103500441 |
0.384 |
|
| 2001 |
Briggs A, Sculpher M, Dawson J, Malchau H. Pod14: Cost-Effectiveness Analysis Of The Spectron Versus Charnley Hip Prostheses Value in Health. 4: 471. DOI: 10.1016/S1098-3015(11)71661-8 |
0.328 |
|
| 2001 |
Delaney B, Wilson S, Roalfe A, Briggs A, Hobbs F. Empirical treatment or prompt endoscopy The Lancet. 357: 1366. DOI: 10.1016/S0140-6736(00)04492-5 |
0.371 |
|
| 2000 |
Delaney BC, Wilson S, Roalfe A, Roberts L, Redman V, Wearn A, Briggs A, Hobbs FDR. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. The Lancet. 356: 1965-1969. PMID 11130524 DOI: 10.1016/S0140-6736(00)03308-0 |
0.37 |
|
| 2000 |
Briggs A. Economic evaluation and clinical trials: Size matters British Medical Journal. 321: 1362-1363. PMID 11099268 DOI: 10.1136/Bmj.321.7273.1362 |
0.363 |
|
| 2000 |
Raikou M, Briggs A, Gray A, McGuire A. Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. Health Economics. 9: 191-198. PMID 10790698 DOI: 10.1002/(Sici)1099-1050(200004)9:3<191::Aid-Hec510>3.0.Co;2-1 |
0.354 |
|
| 2000 |
Briggs A, Gray A. Using cost effectiveness information. Bmj. 320: 246-246. PMID 10642242 DOI: 10.1136/Bmj.320.7229.246 |
0.374 |
|
| 1999 |
Briggs A. Economics notes. Handling uncertainty in economic evaluation British Medical Journal. 318: 120. PMID 10398643 DOI: 10.1136/Bmj.319.7202.120 |
0.347 |
|
| 1998 |
Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. Journal of Health Services Research & Policy. 3: 233-245. PMID 10187204 DOI: 10.1177/135581969800300410 |
0.363 |
|
| 1998 |
Briggs A, Sculpher M. An Introduction To Markov Modelling For Economic Evaluation Pharmacoeconomics. 13: 397-409. PMID 10178664 DOI: 10.2165/00019053-199813040-00003 |
0.3 |
|
| 1998 |
Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Economics. 7: 723-740. PMID 9890333 DOI: 10.1002/(Sici)1099-1050(199812)7:8<723::Aid-Hec392>3.0.Co;2-O |
0.363 |
|
| 1998 |
Briggs A, Sculpher M, Britton A, Murray D, Fitzpatrick R. The costs and benefits of primary total hip replacement. How likely are new prostheses to be cost-effective? International Journal of Technology Assessment in Health Care. 14: 743-761. PMID 9885464 DOI: 10.1017/S0266462300012058 |
0.312 |
|
| 1998 |
Fitzpatrick R, Shortall E, Sculpher M, Murray D, Morris R, Lodge M, Dawson J, Carr A, Britton A, Briggs A. Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses. Health Technology Assessment. 2: 1-64. DOI: 10.3310/Hta2200 |
0.324 |
|
| 1997 |
Briggs A, Fenn P. Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios' Health Economics. 6: 491-495. PMID 9353649 DOI: 10.1002/(Sici)1099-1050(199709)6:5<491::Aid-Hec293>3.0.Co;2-R |
0.337 |
|
| 1996 |
Sharples LD, Briggs A, Caine N, McKenna M, Buxton M. A model for analyzing the cost of main clinical events after cardiac transplantation. Transplantation. 62: 615-621. PMID 8830825 DOI: 10.1097/00007890-199609150-00013 |
0.35 |
|
| 1994 |
Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis Health Economics. 3: 95-104. PMID 8044216 DOI: 10.1002/Hec.4730030206 |
0.328 |
|
| 1994 |
Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. The Medical Journal of Australia. 160: 268-272. DOI: 10.5694/J.1326-5377.1994.Tb125830.X |
0.325 |
|
| Show low-probability matches. |
